ProPhase Labs (NASDAQ:PRPH) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a research report released on Monday morning. The brokerage issued a sell rating on the stock.

ProPhase Labs Price Performance

Shares of NASDAQ:PRPH opened at $0.57 on Monday. ProPhase Labs has a twelve month low of $0.22 and a twelve month high of $7.48. The company’s 50 day moving average is $0.54 and its 200 day moving average is $1.49. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48. The company has a market cap of $13.61 million, a PE ratio of -0.45 and a beta of -0.37.

Institutional Investors Weigh In On ProPhase Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRPH. Sheets Smith Wealth Management acquired a new stake in ProPhase Labs during the fourth quarter worth about $158,000. Perritt Capital Management Inc grew its stake in shares of ProPhase Labs by 129.1% during the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after purchasing an additional 107,068 shares during the period. Warberg Asset Management LLC acquired a new stake in shares of ProPhase Labs during the 4th quarter worth approximately $77,000. Renaissance Technologies LLC grew its stake in shares of ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after purchasing an additional 71,375 shares during the period. Finally, HighTower Advisors LLC grew its stake in shares of ProPhase Labs by 32.2% during the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after purchasing an additional 57,736 shares during the period. 9.45% of the stock is owned by institutional investors and hedge funds.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.